Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $200.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective lifted by JPMorgan Chase & Co. from $168.00 to $200.00 in a report published on Tuesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock.

Other equities analysts have also recently issued research reports about the stock. Evercore ISI lifted their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 18th. The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price on the stock. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $204.64.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $163.24 on Tuesday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $169.37. The stock has a market cap of $9.91 billion, a price-to-earnings ratio of -22.99 and a beta of 0.62. The firm’s 50-day simple moving average is $140.63 and its 200 day simple moving average is $135.50.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new position in Ascendis Pharma A/S in the 4th quarter valued at approximately $174,000. Woodline Partners LP grew its stake in Ascendis Pharma A/S by 35.2% in the 4th quarter. Woodline Partners LP now owns 317,642 shares of the biotechnology company’s stock valued at $43,730,000 after buying an additional 82,624 shares in the last quarter. Zimmer Partners LP grew its stake in Ascendis Pharma A/S by 24.2% in the 4th quarter. Zimmer Partners LP now owns 96,900 shares of the biotechnology company’s stock valued at $13,340,000 after buying an additional 18,900 shares in the last quarter. Vestal Point Capital LP grew its position in shares of Ascendis Pharma A/S by 108.0% during the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company’s stock valued at $71,588,000 after purchasing an additional 270,000 shares in the last quarter. Finally, Soleus Capital Management L.P. purchased a new position in shares of Ascendis Pharma A/S during the 4th quarter valued at $19,824,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.